Hostname: page-component-8448b6f56d-tj2md Total loading time: 0 Render date: 2024-04-24T19:40:55.970Z Has data issue: false hasContentIssue false
  • English
  • Français

Plasminogen activator inhibitor-1 and haemostasis in obesity

Published online by Cambridge University Press:  05 March 2007

Nicola J. Mutch ,
Heather M. Wilson  and
Nuala A. Booth
Nicola J. Mutch
Affiliation:
Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK
Heather M. Wilson
Affiliation:
Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK
Nuala A. Booth*
Affiliation:
Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK
*
*Corresponding author: Dr Nuala Booth, fax +44 1224 273144, email n.a.booth@aberdeen.ac.uk
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The connection between obesity and disordered haemostasis is well established, but incompletely understood. There is a strong link between inhibition of fibrinolysis and obesity, and elevation of the plasma inhibitor, plasminogen activator inhibitor-1 (PAI-1), is regarded as a central factor. Here we explore the increased risk of atherothrombotic disorders in obese subjects, and the evidence for metabolic and genetic causes. There is a clear relationship between plasma PAI-1 and obesity, and adipose tissue synthesises PAI-1, as has been shown in mouse and rat models, and more recently in human material. This tissue also produces several effector molecules that can up regulate PAI-1. These molecules include transforming growth factor b, tumour necrosis factor a, angiotensin II and interleukin 6, all of which up regulate PAI-1 in various cell types. The issue of whether adipose tissue directly contributes to plasma PAI-1, or whether it primarily contributes indirectly, its products stimulating other cells to produce PAI-1 that feeds into the plasma pool, is not yet resolved. Finally, we briefly examine other proteins of haemostasis that are products of adipose tissue. Further studies are needed to define the regulation of these proteins, in adipose tissue itself and in other cells influenced by its products, in order to extend recent insights into the links between obesity and haemostasis.

Keywords

ObesityPAI-1ThrombosisInsulin resistanceCardiovascular disease
Type
Symposium on ‘New perspectives on adipose tissue function’
Information
Proceedings of the Nutrition Society , Volume 60 , Issue 3 , August 2001 , pp. 341 - 347
Copyright
Copyright © The Nutrition Society 2001

References

Aikawa, M, Voglic, SJ, Sugiyama, S, Rabkin, E, Taubman, MB, Fallon, JT & Libby, P (1999) Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation 100, 1215–1222.CrossRefGoogle ScholarPubMed
Ailhaud, G (1999) Cross talk between adipocytes and their precursors: Relationships with adipose tissue development and blood pressure. Annals of the New York Academy of Sciences 892, 127–133.CrossRefGoogle ScholarPubMed
Alessi, MC, Bastelica, D, Morange, P, Berthet, B, Leduc, I, Verdier, M, Geel, O & Juhan-Vague, I (2000) Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 49, 1374–1380.CrossRefGoogle ScholarPubMed
Alessi, MC, Parrot, G, Guenoun, E, Scelles, V, Vague, P & Juhan-Vague, I (1995) Relation between plasma PAI activity and adipsin levels. Thrombosis and Haemostasis 74, 1200–1202.Google ScholarPubMed
Alessi, MC, Peiretti, F, Morange, P, Henry, M, Nalbone, G & Juhan-Vague, I (1997) Production of plasminogen activator inhibitor 1 by human adipose tissue – Possible link between visceral fat accumulation and vascular disease. Diabetes 46, 860–867.CrossRefGoogle ScholarPubMed
Andreasen, PA, Georg, B, Lund, LR, Riccio, A & Stacy, SN (1990) Plasminogen activator inhibitors: hormonally regulated serpins. Molecular and Cellular Endocrinology 68, 1–19.CrossRefGoogle ScholarPubMed
Anfosso, F, Chomiki, N, Alessi, MC, Vague, P & Juhan-Vague, I (1993) Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line HepG2: metformin inhibits the stimulating effect of insulin. Journal of Clinical Investigation 91, 2185–2193.CrossRefGoogle Scholar
Bennett, NB, Ogston, CM, McAndrew, GM & Ogston, D (1966) Studies on the fibrinolytic enzyme system in obesity. Journal of Clinical Pathology 19, 241–243.CrossRefGoogle ScholarPubMed
Birgel, M, Gottschling-Zeller, H, Röhrig, K & Hauner, H (2000) Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes. Arteriosclerosis Thrombosis and Vascular Biology 20, 1682–1687.CrossRefGoogle ScholarPubMed
Booth, NA (1999) Fibrinolysis and thrombosis. Bailliére's Clinical Haematology 12, 423–433.Google ScholarPubMed
Brown, NJ, Nadeau, J & Vaughan, DE (1997) Stimulation of tissue-type plasminogen activator in vivo by infusion of bradykinin. Thrombosis and Haemostasis 96, 442–447.Google Scholar
Carmassi, F, Morale, M, Ferrini, L, Dell'Omo, G, Ferdeghini, M, Pedrinelli, R & De Negri, F (1999) Local insulin infusion stimulates expression of plasminogen activator inhibitor-1 and tissue-type plasminogen activator in normal subjects. American Journal of Medicine 107, 344–350.CrossRefGoogle ScholarPubMed
Carmeliet, P & Collen, D (1996) Targeted gene manipulation and transfer of the plasminogen and coagulation systems in mice. Fibrinolysis 10, 195–213.CrossRefGoogle Scholar
Chaldakov, GN, Fiore, M, Ghenev, PI, Stankulov, IS & Aloe, L (2000) Atherosclerotic lesions: possible interactive involvement of intima, adventitia and associated adipose tissue. International Medical Journal 7, 43–49.Google Scholar
Cigolini, M, Targher, G, Andreis, IAB, Tonoli, M, Agostino, G & DeSandre, G (1996) Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arteriosclerosis Thrombosis and Vascular Biology 16, 368–374.CrossRefGoogle ScholarPubMed
Cigolini, M, Tonoli, M, Borgato, L, Frigotto, L, Manzato, F, Zeminian, S, Cardinale, C, Camin, M, Chiaramonte, E, De Sandre, G & Lunardi, C (1999) Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-α? Atherosclerosis 143, 81–90.CrossRefGoogle ScholarPubMed
Declerck, PJ, de Mol, M, Alessi, MO, Baudner, S, Paques, EP, Preissner, KT, Muller-Berghaus, G & Collen, D (1988) Purification and characterization of a plasminogen activator inhibitor I binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). Journal of Biological Chemistry 263, 15454–15461.CrossRefGoogle ScholarPubMed
Erickson, LA, Fici, GJI, Lund, JE, Boyle, TP, Polites, HG & Marotti, KR (1990) Development of venous occlusions in mice transgenic for plasminogen activator inhibitor 1 gene. Nature 346, 74–76.CrossRefGoogle ScholarPubMed
Eriksson, P, Reynisdottir, S, Lönnqvist, F, Stemme, V, Hamsten, A & Arner, P (1998) Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia 41, 65–71.CrossRefGoogle ScholarPubMed
Eriksson, P, Van Harmelen, V, Hoffsstedt, J, Lundquist, P, Vidal, H, Stemme, V, Hamsten, A, Arner, P & Reynisdottir, S (2000) Regional variation in plasminogen activator inhibitor-1 expression in adipose tissue from obese individuals. Thrombosis and Haemostasis 83, 545–548.Google ScholarPubMed
Fay, W, Shapiro, A, Shih, J, Schleef, RR & Ginsburg, D (1992) Complete deficiency of plasminogen activator inhibitor type-1 due to a frameshift mutation. New England Journal of Medicine 327, 1729–1733.CrossRefGoogle Scholar
Fearnley, GR, Chakrabarti, R & Avis, PRD (1963) Blood fibrinolytic activity in diabetes mellitus and its bearing on ischaemic heart disease and obesity. British Medical Journal i, 921–923.CrossRefGoogle Scholar
Feener, EP, Northup, JM, Aiello, LP & King, G (1995) Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. Journal of Clinical Investigation 95, 1353–1362.CrossRefGoogle ScholarPubMed
Ferguson, MA, Gutin, B, Owens, S, Litaker, M, Tracy, RP & Allison, J (1998) Fat distribution and hemostatic measures in obese children. American Journal of Clinical Nutrition 67, 1136–1140.CrossRefGoogle ScholarPubMed
Folsom, AR, Qamhieh, HT, Wing, RR, Jeffery, RW, Stinson, VL, Kuller, LH & Wu, KK (1993) Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arteriosclerosis and Thrombosis 13, 162–169.CrossRefGoogle ScholarPubMed
Hamdan, AD, Quist, WC, Gagne, JB & Feener, EP (1996) Angiotensin converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon injured rat aorta. Circulation 137, 7–12.Google Scholar
Hotamisligil, GS, Shargill, NS & Spiegelman, BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259, 87–91.CrossRefGoogle ScholarPubMed
Hotta, K, Funahashi, T, Arita, Y, Takahushi, M, Matsuda, M, Okamoto, Y, Iwahashi, H, Kuriyama, H, Ouchi, N, Maeda, K, Nishida, M, Kihara, S, Sakai, N, Nakajima, T, Hasegawa, K, Muraguchi, M, Ohmoto, Y, Nakamura, T, Yamashita, S, Hanafusa, T & Matsuzawa, Y (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arteriosclerosis Thrombosis and Vascular Biology 20, 1595–1599.CrossRefGoogle ScholarPubMed
Juhan-Vague, I & Alessi, MC (1993) Plasminogen activator inhibitor 1 and atherothrombosis. Thrombosis and Haemostasis 70, 138–143.Google ScholarPubMed
Juhan-Vague, I & Alessi, MC (1997) PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thrombosis and Haemostasis 78, 656–660.Google ScholarPubMed
Juhan-Vague, I, Pyke, SDM, Alessi, MC, Jespersen, J, Haverkate, F & Thompson, SG (1996) Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 94, 2057–2063.CrossRefGoogle ScholarPubMed
Karlsson, C, Lindell, K, Ottoson, M, Sjostrom, L, Carlsson, B & Carlsson, LM (1998) Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. Journal of Clinical Endocrinology and Metabolism 83, 3925–3929.Google ScholarPubMed
Kluft, C, Jie, AFH, Rijken, DC & Verheijen, JH (1988) Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1). Thrombosis and Haemostasis 59, 329–332.Google ScholarPubMed
Kockx, M, Leenan, R, Seidell, J, Princen, HMG & Kooistra, T (1999) Relationship between visceral fat and PAI-1 in overweight men and women before and after weight loss. Thrombosis and Haemostasis 82, 1490–1496.CrossRefGoogle ScholarPubMed
Kooistra, T, Bosma, PJ, Tons, HAM, van den Berg, AP, Meyer, P & Princen, HMG (1989) Plasminogen activator inhibitor-1: biosynthesis and messenger RNA level are increased by insulin in cultured human hepatocytes. Thrombosis and Haemostasis 62, 723–728.Google ScholarPubMed
Kruithof, EKO, Gudinchet, A & Bachmann, F (1988) Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thrombosis and Haemostasis 59, 7–12.Google ScholarPubMed
Landin, K, Stigendal, L, Eriksson, E, Krotiewski, M, Risberg, B, Tengborn, L & Smith, U (1990) Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 39, 1044–1048.CrossRefGoogle ScholarPubMed
Lane, DA & Grant, PJ (2000) Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 95, 1517–1532.CrossRefGoogle ScholarPubMed
Loskutoff, DJ (1991) Regulation of PAI-1 gene expression. Fibrinolysis 5, 197–206.CrossRefGoogle Scholar
Loskutoff, DJ, Fujisawa, K & Samad, F (2000) The fat mouse – a powerful genetic model to study hemostatic gene expression in obesity/NIDDM. Annals of the New York Academy of Sciences 902, 272–282.CrossRefGoogle Scholar
Lundgren, CH, Brown, SL, Nordt, TK, Sobel, BE & Fujii, S (1996) Elaboration of type-1 plasminogen activator inhibitor from adipocytes – A potential pathogenetic link between obesity and cardiovascular disease. Circulation 93, 106–110.CrossRefGoogle ScholarPubMed
McGill, JB, Schneider, DJ, Arfken, CL, Lucore, SL & Sobel, BE (1994) Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 43, 104–109.CrossRefGoogle ScholarPubMed
Marckmann, P, Toubro, S & Astrup, A (1998) Sustained improvement in blood lipids, coagulation, and fibrinolysis after major weight loss in obese subjects. European Journal of Clinical Nutrition 52, 329–333.CrossRefGoogle ScholarPubMed
Mavri, A, Stegnar, M, Krebs, M, Sentocnik, JT, Geiger, M & Binder, BR (1999) Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women. Arteriosclerosis Thrombosis and Vascular Biology 19, 1582–1587.CrossRefGoogle ScholarPubMed
Morange, PE, Alessi, MC, Verdier, M, Casanova, D, Megalon, G & Juhan-Vague, I (1999) PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level. Arteriosclerosis Thrombosis and Vascular Biology 19, 1361–1365.CrossRefGoogle ScholarPubMed
Morange, PE, Lijnen, HR, Alessi, MC, Kopp, F, Collen, D & Juhan-Vague, I (2000) Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arteriosclerosis Thrombosis and Vascular Biology 20, 1150–1154.CrossRefGoogle Scholar
Nordt, TK, Sawa, H, Fujii, S & Sobel, BE (1995) Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 91, 764–770.CrossRefGoogle ScholarPubMed
Olson, JA, Shiverick, KT, Ogilvie, S, Buhi, WC & Raizada, MK (1991) Angiotensin II induces the secretion of PAI-1 and a tissue metalloproteinase inhibitor related protein from rat brain astrocytes. Proceedings of the National Academy of Sciences USA 88, 1928–1932.CrossRefGoogle Scholar
Pandolfi, A, Giaccari, A, Polishuck, R, Alberta, MM, Pellegrini, G, Morviducci, L, Vitacolonna, E, Buongiorno, AM, Capani, F & Consoli, A (2000) Diabetes mellitus induces decreased plasma fibrinolytic activity and increased tissue synthesis of plasminogen activator inhibitor-1 (PAI-1) in the rat. Fibrinolysis and Proteolysis 14, 261–267.CrossRefGoogle Scholar
Peraldi, P & Spiegelman, BM (1997) Studies of the mechanism of inhibition of insulin signaling by tumor necrosis factor-alpha. Journal of Endocrinology 155, 219–220.CrossRefGoogle ScholarPubMed
Potter Van Loon, BJ, Rijken, DC, Brommer, EJP & van der Maas, APC (1992) The amount of plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Thrombosis and Haemostasis 67, 101–105.Google ScholarPubMed
Primrose, JN, Davies, JA, Prentice, CRM, Hughes, R & Johnston, D (1992) Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity. Thombosis and Haemostasis 68, 396–399.Google ScholarPubMed
Reaven, GM (1988) Role of insulin resistance in human disease. Diabetes 37, 1595–1607.CrossRefGoogle ScholarPubMed
Ridker, PM, Gaboury, CL, Conlin, PR, Seely, EW, Williams, GH & Vaughan, DE (1993) Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 87, 1969–1973.CrossRefGoogle ScholarPubMed
Robbie, LA, Bennett, B, Croll, AM, Brown, PAJ & Booth, NA (1996a) Proteins of the fibrinolytic system in human thrombi. Thrombosis and Haemostasis 75, 127–133.Google ScholarPubMed
Robbie, LA, Booth, NA, Brown, PAJ & Bennett, B (1996b) Inhibitors of fibrinolysis are elevated in the atherosclerotic plaque. Arteriosclerosis Thrombosis and Vascular Biology 16, 539–545.CrossRefGoogle ScholarPubMed
Rosenbaum, M, Leibel, RL & Hirsch, J (1997) Obesity. New England Journal of Medicine 337, 396–407.CrossRefGoogle ScholarPubMed
Samad, F & Loskutoff, DJ (1996) Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Molecular Medicine 2, 568–582.CrossRefGoogle ScholarPubMed
Samad, F & Loskutoff, DJ (1997) The fat mouse: A powerful genetic model to study elevated plasminogen activator inhibitor 1 in Obesity/NIDDM. Thrombosis and Haemostasis 78, 652–655.Google Scholar
Samad, F, Pandey, M, Bell, PA & Loskutoff, DJ (2000) Insulin continues to induce plasminogen activator inhibitor 1 gene expression in insulin-resistant mice and adipocytes. Molecular Medicine 6, 680–682.CrossRefGoogle ScholarPubMed
Samad, F, Pandey, M & Loskutoff, DJ (1998) Tissue factor gene expression in the adipose tissues of obese mice. Proceedings of the National Academy of Sciences USA 95, 7591–7596.CrossRefGoogle ScholarPubMed
Samad, F, Uysal, KT, Wiesbrock, SM, Pandey, M, Hotamisligil, GS & Loskutoff, DJ (1999) Tumor necrosis factor a is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proceedings of the National Academy of Sciences USA 96, 6902–6907.CrossRefGoogle ScholarPubMed
Samad, F, Yamamoto, K & Loskutoff, DJ (1996) Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo – induction by tumor necrosis factor-alpha and lipopolysaccharide. Journal of Clinical Investigation 97, 37–46.CrossRefGoogle ScholarPubMed
Samad, F, Yamamoto, K, Pandey, M & Loskutoff, DJ (1997) Elevated expression of transforming growth factor-beta in adipose tissue from obese mice. Molecular Medicine 3, 37–48.CrossRefGoogle ScholarPubMed
Sawdey, MS & Loskutoff, DJ (1991) Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo: tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-a, and transforming growth factor-b. Journal of Clinical Investigation 88, 1346–1353.CrossRefGoogle Scholar
Schling, P, Mallow, H, Trindl, A & Loffler, G (1999) Evidence for a local renin angiotensin system in primary cultured human preadipocytes. International Journal of Obesity and Related Metabolic Disorders 23, 336–341.CrossRefGoogle ScholarPubMed
Schneider, DJ & Sobel, BE (1991) Augmentation of synthesis of plasminogen activator inhibitor type-1 by insulin and insulin-like growth factor type 1 – implications for vascular disease in hyperinsulinemic states. Proceedings of the National Academy of Sciences USA 88, 9959–9963.CrossRefGoogle ScholarPubMed
Schneiderman, J, Sawdey, MS, Keeton, MR, Bordin, GM, Bernstein, EF, Dilley, RB & Loskutoff, DJ (1992) Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proceedings of the National Academy of Sciences USA 89, 6998–7002.CrossRefGoogle ScholarPubMed
Shimomura, I, Funahashi, T, Takahashi, M, Maeda, K, Kotani, K, Nakamura, T, Yamashita, S, Miura, M, Fukuda, Y, Takemura, K, Tokunaga, K & Matsuzawa, Y (1996) Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nature Medicine 2, 800–803.CrossRefGoogle ScholarPubMed
Simpson, AJ, Booth, NA, Moore, NR & Bennett, B (1991) Plasminogen activator inhibitor (PAI-1): distribution in human tissues. Journal of Clinical Pathology 44, 139–143.CrossRefGoogle Scholar
Smith, EB (1994) Fibrin deposition and fibrin degradation products in atherosclerotic plaques. Thrombosis Research 75, 329–335.CrossRefGoogle ScholarPubMed
Spiegelman, BM & Flier, JS (1996) Adipogenesis and obesity: Rounding out the big picture. Cell 87, 377–389.CrossRefGoogle ScholarPubMed
Sundell, IB, Dahlen, GH & Ranby, M (1991) Diet-induced changes in glucose and triglycerides are associated with changes in plasminogen-activator inhibitor levels. Haemostasis 21, 175–180.Google ScholarPubMed
Sundell, IB, Dahlgren, S, Ranby, M, Lundin, E, Stenling, R & Nilsson, TK (1989) Reduction of elevated plasminogen activator inhibitor levels during modest weight loss. Fibrinolysis 3, 51–53.CrossRefGoogle Scholar
Vague, P, Juhan-Vague, I, Aillaud, MF, Badier, C, Viard, R, Alessi, MC & Collen, D (1986) Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 35, 250–253.CrossRefGoogle ScholarPubMed
Vague, P, Juhan-Vague, I, Chabert, V, Alessi, MC & Atlan, C (1989) Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. Metabolism 38, 913–915.CrossRefGoogle ScholarPubMed
Vaughan, DE (1998) Fibrinolytic balance, the renin-angiotensin system and atherosclerotic disease. European Heart Journal 19, G9–G12.Google ScholarPubMed
Wilson, HM, Haites, NE & Booth, NA (1997) Effect of angiotensin II on plasminogen activator inhibitor-1 production by cultured human mesangial cells. Nephron 77, 197–204.CrossRefGoogle ScholarPubMed
Yudkin, JS, Coppack, SW, Bulmer, K, Rawesh, A & Mohamed-Ali, V (1999) Lack of evidence for secretion of plasminogen activator inhibitor-1 by human subcutaneous adipose tissue in vivo. Thrombosis Research 96, 1–9.CrossRefGoogle ScholarPubMed
Yudkin, JS, Kumari, M, Humphries, SE & Mohamed-Ali, V (2000) Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148, 209–214.CrossRefGoogle ScholarPubMed
Zorad, S, Fickova, M, Zelezna, B, Macho, L & Kral, JG (1995) The role of angiotensin II and its receptors in regulation of adipose tissue metabolism and cellularity. General Physiology and Biophysics 14, 383–391.Google ScholarPubMed